Artículos de revistas
Platelet-derived growth factor BB and DD and angiopoietin1 are altered in follicular fluid from polycystic ovary syndrome patients
Fecha
2014-07-23Registro en:
Scotti, Leopoldina; Parborell, Maria Fernanda Agustina; Irusta, Griselda; de Zuñiga, Ignacio; Bisioli, Claudio; et al.; Platelet-derived growth factor BB and DD and angiopoietin1 are altered in follicular fluid from polycystic ovary syndrome patients; Wiley; Molecular Reproduction and Development; 81; 8; 23-7-2014; 748-756
1040-452X
1098-2795
Autor
Scotti, Leopoldina
Parborell, Maria Fernanda Agustina
Irusta, Griselda
de Zuñiga, Ignacio
Bisioli, Claudio
Pettorossi, Hernan
Tesone, Marta
Abramovich, Dalhia Nurit
Resumen
Polycystic ovary syndrome (PCOS) is the most common endocrinological pathology among women of reproductive age, and is characterized by abnormalities in ovarian angiogenesis, among other features. Consistent with this association, follicular fluid (FF) concentration and ovarian expression of vascular endothelial growth factor (VEGF) are increased in PCOS patients. In this study, we examined the protein levels of platelet-derived growth factor (PDGF) BB and DD (PDGFBB and PDGFDD), angiopoietin 1 and 2 (ANGPT1 and ANGPT2), and their soluble receptor sTIE2 in FF from PCOS and control patients undergoing assisted reproductive techniques. We also analyzed the effect of FF from PCOS and control patients on tight and adherens junction protein expression[0] in an endothelial cell line. PDGFBB and PDGFDD were significantly whereas ANGPT1 concentration was significantly higher in FF from PCOS patients than from control patients. No changes were found in the concentration of ANGPT2 or sTIE2. Expression of claudin-5 was significantly increased in endothelial cells incubated for 24 h in the presence of FF from PCOS versus from control patients, while vascular-endothelial cadherin, β-catenin, and zonula occludens 1 expression were unchanged. The changes observed in the levels of PDGF isoforms and ANGPT1 may prevent VEGF-induced vascular permeability in the PCOS ovary by regulating endothelial-cell-junction protein levels. Restoring the levels of angiogenic factors may provide new insights into PCOS treatment and the prevention of ovarian hyperstimulation syndrome in affected women.